Allogeneic versus autologous cell sources present trade-offs in availability, cost, immune risk

https://privatebin.net/?73587e385f9deaf6#4UBg5bMdUk3cFQqBYG8pXQmn1JGMEuHg74xP5vE79CYv

Allogeneic versus autologous cell sources present trade-offs in availability, cost, immune risk, and standardization that shape clinical strategy and manufacturing.